Related references
Note: Only part of the references are listed.Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
R. Bianco et al.
BRITISH JOURNAL OF CANCER (2008)
Pulmonary complications of novel antineoplastic agents for solid tumors
Bobbak Vahid et al.
CHEST (2008)
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies
Monica M. Mita et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors
Anne O'Donnell et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma
John G. Kuhn et al.
CLINICAL CANCER RESEARCH (2007)
Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications
Joseph Boni et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non-small cell lung cancer
Bruce E. Johnson et al.
CLINICAL CANCER RESEARCH (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model
Michael R. Milam et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Molecular basis for sunitinib efficacy and future clinical development
Sandrine Faivre et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer
Manuel Hidalgo et al.
CLINICAL CANCER RESEARCH (2006)
Current development of mTOR inhibitors as anticancer agents
Sandrine Faivre et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
GV Thomas et al.
NATURE MEDICINE (2006)
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
S Faivre et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis
K Hamada et al.
GENES & DEVELOPMENT (2005)
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor
S Hara et al.
ANNALS OF ONCOLOGY (2005)
Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma
HL Kim et al.
JOURNAL OF UROLOGY (2005)
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
MB Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer
E Raymond et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma
D Aguirre et al.
APOPTOSIS (2004)
Loss of tumor suppressor protein PTEN during renal carcinogenesis
W Brenner et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis
M Velickovic et al.
MODERN PATHOLOGY (2002)
Phosphatidylinositol 3-kinase/Akt signaling is neither required for hypoxic stabilization of HIF-1α nor sufficient for HIF-1-dependent target gene transcription
AM Arsham et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
M Guba et al.
NATURE MEDICINE (2002)
Share Paper
